Kazuo Fujihara Selected Research

anti-aquaporin 4 autoantibody

1/2016	Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India.
12/2014	Audiological evidence of therapeutic effect of steroid treatment in neuromyelitis optica with hearing loss.
1/2014	[A case of myelitis with anti-aquaporin 4 antibody concomitant with immune thrombocytopenic purpura].
1/2012	Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity.
3/2009	[Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].
5/2008	[Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuo Fujihara Research Topics

Disease

104	Neuromyelitis Optica (Devic's Disease) 06/2024 - 04/2004
45	Multiple Sclerosis 11/2023 - 11/2002
27	Optic Neuritis (Retrobulbar Neuritis) 12/2023 - 01/2011
23	Demyelinating Diseases (Demyelinating Disease) 12/2023 - 08/2007
11	Myelitis 01/2023 - 11/2006
10	Encephalitis (Encephalitis, Rasmussen) 01/2023 - 11/2009
7	Infections 05/2022 - 01/2012
5	Inflammation (Inflammations) 01/2023 - 03/2011
5	Leukocytosis (Pleocytosis) 01/2019 - 11/2007
5	Necrosis 06/2013 - 10/2004
4	Encephalomyelitis (Myeloencephalitis) 01/2023 - 12/2015
4	Pain (Aches) 01/2021 - 01/2012
4	Autoimmune Diseases (Autoimmune Disease) 11/2019 - 05/2003
4	Transverse Myelitis (Necrotizing Myelitis) 01/2016 - 01/2012
3	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 01/2023 - 10/2015
3	Fatigue 01/2021 - 06/2015
3	Blindness (Hysterical Blindness) 10/2019 - 11/2006
3	Disease Progression 01/2018 - 10/2015
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2015 - 10/2004
3	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 02/2005 - 08/2003
2	Nasopharyngitis 06/2024 - 05/2021
2	Ganglion Cysts (Ganglion) 01/2023 - 01/2022
2	Human Influenza (Influenza) 05/2022 - 11/2014
2	Respiratory Tract Infections (Respiratory Tract Infection) 05/2021 - 01/2019
2	Headache (Headaches) 05/2021 - 01/2019
2	Aphasia (Dysphasia) 01/2018 - 09/2014
2	Poisoning 01/2016 - 05/2015
2	Central Nervous System Diseases (CNS Diseases) 12/2015 - 10/2015
2	Spinal Cord Diseases 03/2015 - 08/2003
2	Granuloma 03/2011 - 02/2002
2	Opticospinal Multiple Sclerosis 01/2011 - 11/2007
2	Polymyositis 11/2006 - 02/2002
2	Myositis (Idiopathic Inflammatory Myopathies) 12/2005 - 02/2002
1	COVID-19 06/2024
1	Pneumonia (Pneumonitis) 06/2024
1	Urinary Tract Infections (Urinary Tract Infection) 06/2024
1	Respiratory Insufficiency (Respiratory Failure) 06/2024
1	Viral Pneumonia 06/2024
1	Arthralgia (Joint Pain) 06/2024
1	Renal Tubular Acidosis (Distal Renal Tubular Acidosis) 01/2023
1	Hypokalemia 01/2023
1	Inappropriate ADH Syndrome (SIADH) 01/2023
1	Nephrogenic Diabetes Insipidus 01/2023
1	Relapsing-Remitting Multiple Sclerosis 01/2023
1	Quadriplegia (Spastic Quadriplegia) 01/2023
1	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 01/2023
1	Hepatitis E 05/2022
1	Vision Disorders (Hemeralopia) 01/2022
1	Atrophy 01/2022

Drug/Important Bio-Agent (IBA)

37	Immunoglobulin G (IgG)IBA 06/2024 - 12/2004
34	AntibodiesIBA 07/2023 - 11/2009
30	AutoantibodiesIBA 01/2023 - 12/2004
29	Myelin-Oligodendrocyte GlycoproteinIBA 12/2023 - 02/2014
22	Aquaporin 4IBA 01/2023 - 11/2010
13	Complement System Proteins (Complement)IBA 01/2023 - 06/2008
11	Biomarkers (Surrogate Marker)IBA 01/2023 - 09/2010
11	Aquaporins (Water Channels)IBA 01/2023 - 05/2007
9	inebilizumabIBA 06/2024 - 10/2019
8	eculizumab FDA Link 01/2023 - 01/2019
8	ChemokinesIBA 11/2016 - 08/2003
7	Proteins (Proteins, Gene)FDA Link 12/2023 - 01/2005
7	Oligoclonal BandsIBA 01/2018 - 06/2004
6	satralizumabIBA 02/2024 - 11/2019
6	Retinaldehyde (Retinal)IBA 01/2023 - 12/2010
6	anti-aquaporin 4 autoantibodyIBA 01/2016 - 05/2008
5	Glial Fibrillary Acidic ProteinIBA 01/2023 - 05/2008
5	SteroidsIBA 05/2022 - 12/2014
5	InterferonsIBA 06/2015 - 10/2004
5	AntigensIBA 09/2011 - 05/2007
4	Monoclonal AntibodiesIBA 02/2024 - 06/2008
4	Methylprednisolone FDA LinkGeneric 01/2020 - 05/2008
4	CytokinesIBA 11/2016 - 10/2004
3	Prednisolone (Predate)FDA LinkGeneric 04/2021 - 05/2015
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 08/2014
3	Immunosuppressive Agents (Immunosuppressants)IBA 11/2019 - 11/2007
3	Protons (Proton)IBA 01/2016 - 04/2003
3	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2015 - 10/2003
3	Therapeutic UsesIBA 12/2014 - 02/2005
3	Immunoglobulins (Immunoglobulin)IBA 11/2009 - 11/2006
3	Interferon-alpha (Interferon Alfa)IBA 02/2005 - 08/2003
2	Rituximab (Mabthera)FDA Link 01/2021 - 07/2011
2	EnzymesIBA 01/2020 - 08/2007
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2018 - 03/2014
2	Myelin Basic ProteinIBA 03/2017 - 05/2012
2	EpitopesIBA 10/2016 - 01/2011
2	Carbon MonoxideIBA 01/2016 - 05/2015
2	Interferon-betaIBA 02/2008 - 11/2007
1	PotassiumIBA 01/2023
1	Vasopressins (Vasopressin)IBA 01/2023
1	Dimethyl FumarateIBA 01/2023
1	ElectrolytesIBA 01/2023
1	Complement C5 (Complement 5)IBA 01/2023
1	SodiumIBA 01/2023
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2023
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 01/2023
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2022

Therapy/Procedure

26	Therapeutics 06/2024 - 10/2003
3	Secondary Prevention 01/2023 - 01/2021
2	Immunotherapy 01/2012 - 02/2002
1	Patient Admission (Patient Admissions) 11/2023